Drug Trial Radar · NCT07399171
Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
May 12, 2026
Primary completion
Feb 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Halia Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: To demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score. Secondary Objectives: * To assess the effects of HT-4253 on tau related blood biomarker progression over the study period. * To assess the effects of HT-4253 on amyloid related blood biomarker progression over the study period. * To assess the safety and tolerability of HT-4253 in the UAE population.
Conditions
- Alzheimers Disease
Interventions
HT-4253Drug
It is anticipated that 112 participants will be randomized to receive HT-4253 (56 in each study arm).
PlaceboOther
It is anticipated that 112 participants will be randomized to receive placebo (56 in each study arm).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary ObjectiveTime frame: 48 weeks
- Primary EndpointTime frame: Week 48
- Primary EndpointTime frame: Week 48
- Primary EndpointTime frame: Week 48
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates · Not yet recruiting
Burjeel Medical City
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates · Recruiting
Sheikh Shakbout Medical City (SSMC)
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.